Pharmacoepidemiology and drug safety · 2026
Prescription Intervals of Medications for Chronic Use: A Cohort Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muddiman Ryan, Donoghue Padraic, Lemus Jessica Gómez, Doherty Ann Sinéad, Boland Fiona, McCarthy Caroline, Moriarty Frank
Аннотация
PURPOSE: In deprescribing studies, a prescription-free gap is typically used to determine if patients discontinued their treatment. An appropriate gap depends on the typical time between prescriptions during continued use. This work aims to characterise the interval between prescriptions of chronic drugs (long-term use) using different methods for a cohort of older people in primary care in Ireland.
METHODS: The prescription interval was analysed for 38 154 patients over 2011-2020 for the 20 most common drug classes in the dataset and the association between covariates and the interval was analysed using a multi-level model. Estimates were also compared with those obtained from the parametric waiting time distribution (pWTD) approach.
RESULTS: Prescription and demographic factors had consistent relationships with prescription intervals across drug classes. Each additional prescription issue was associated with increases in the interval by 5.0 (NSAIDs) to 19.7 days ('other antidepressants'). Full public health cover was associated with a -29.0 day (inhaled adrenergics) to -11.0 day (opioids) change relative to partial cover, whilst other/private health cover had a -17.9 day (benzodiazepines and associated drugs) to -7.1 day (SSRI and SNRIs) change relative to partial cover. The pWTD produced consistent estimates of the population interval for most drugs.
CONCLUSIONS: The prescription interval varied substantially within drug classes, due to patient, practice and unmodelled factors. Variation between practices was effectively explained, with residual variation between patients and within patients. The pWTD approach is useful for describing complex distributions of intervals, and may be more appropriate for inferring a gap than summarising truncated data.
METHODS: The prescription interval was analysed for 38 154 patients over 2011-2020 for the 20 most common drug classes in the dataset and the association between covariates and the interval was analysed using a multi-level model. Estimates were also compared with those obtained from the parametric waiting time distribution (pWTD) approach.
RESULTS: Prescription and demographic factors had consistent relationships with prescription intervals across drug classes. Each additional prescription issue was associated with increases in the interval by 5.0 (NSAIDs) to 19.7 days ('other antidepressants'). Full public health cover was associated with a -29.0 day (inhaled adrenergics) to -11.0 day (opioids) change relative to partial cover, whilst other/private health cover had a -17.9 day (benzodiazepines and associated drugs) to -7.1 day (SSRI and SNRIs) change relative to partial cover. The pWTD produced consistent estimates of the population interval for most drugs.
CONCLUSIONS: The prescription interval varied substantially within drug classes, due to patient, practice and unmodelled factors. Variation between practices was effectively explained, with residual variation between patients and within patients. The pWTD approach is useful for describing complex distributions of intervals, and may be more appropriate for inferring a gap than summarising truncated data.